Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Esercizio ad intervalli ad alta intensità in giovani adulti sopravvissuti a tumori cerebrali pediatrici: uno studio di fattibilità pilota (HYPE)

3 novembre 2026 aggiornato da: Christina Dieli-Conwright, PhD, Dana-Farber Cancer Institute

Esercizio ad intervalli ad alta intensità in giovani adulti sopravvissuti a tumori cerebrali pediatrici: uno studio di fattibilità pilota (HYPE)

The purpose of this study is to determine whether a 16-week virtual, home-based, high-intensity interval training (HIIT) exercise program will improve physical, cognitive, and emotional health among young adult survivors of pediatric brain tumors.

The names of the study interventions involved in this study are/is:

  • High-Intensity Interval Training (HIIT)

Panoramica dello studio

Stato

Reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a Pilot/Feasibility, randomized control, research study that will compare an exercise group to a control group on physical, social, and overall quality of life needs of pediatric brain tumor survivors who are now young adults.

Participants will be randomized (selected at random) for two groups: HIIT program group will complete a 16-week intervention period followed by a 16-week period with no intervention and the waitlisted control group will complete a 16-week period and will perform their usual, daily activities followed by an optional 16-week period in which they can complete the HIIT program.

Research procedures include screening for eligibility, study treatment including in-clinic evaluations of fitness and strength, blood collection, at-home zoom exercise sessions, self-administered activity logs, and survey questionnaires.

Participation in this research study is expected to last about 8 months.

It is expected that about 30 people will take part in this research study.

The Stahl Family Charitable Foundation, Pedal 4 Pediatrics, and the Childhood Brain Tumor Foundation are supporting this research study by providing funding for the study.

Tipo di studio

Interventistico

Iscrizione (Stimato)

30

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Massachusetts
      • Boston, Massachusetts, Stati Uniti, 02215
        • Reclutamento
        • Dana Farber Cancer Institute
        • Contatto:
        • Investigatore principale:
          • Christina M Dieli-Conwright, PhD

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

Da 18 anni a 45 anni (Adulto)

Accetta volontari sani

Sì

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Written informed consent prior to any study-related procedures.
  • At time of study are a young adult, aged 18-45 years.
  • Histologically diagnosed brain tumor during childhood, or currently diagnosed with an IDH-mutant glioma (diagnosed > 18 years).
  • Are at least 2 years post tumor-directed therapy for pediatric brain tumor survivors, or at least 1 year since their most recent surgery, radiation or chemotherapy treatment for IDH-mutant glioma patients (or are deemed able to participate in the study based on the assessment of their treating physician). IDH-mutant glioma patients can participate while on maintenance therapy with an IDH inhibitor.
  • The effects of exercise on the developing fetus are unknown. For this reason, people of child-bearing potential must verify pregnancy status by providing first day of their last menstrual cycle and agree to use adequate contraception (hormonal or barrier method of birth control or abstinence) prior to study entry. Should a person become pregnant or suspect that they are pregnant while participating on the trial, they should inform their treating physician immediately.
  • Medically cleared to participate in exercise by their referring physician or a certified clinical exercise physiologist.
  • If participants have a diagnosis of tumor-related epilepsy, they must have good seizure control, with no generalized seizures in the 6 months preceding enrollment.
  • Are without any other medical conditions that could exacerbate with exercise, such as bone disease (excluding bone metastases) at imminent risk of fracture or uncontrolled cardiopulmonary or metabolic diseases.
  • Speak English and/or Spanish.
  • Currently participate in less than or equal to 60 minutes of moderate or vigorous structured exercise/week.
  • Does not smoke cigarettes or e-cigarettes (no smoking during the previous 12 months). Those who infrequently smoke in social settings will be included. Those who vape will also be included.
  • Willing to travel to DFCI for necessary data collection.
  • Ability to understand and the willingness to sign a written informed consent document

Exclusion Criteria:

  • Diagnosis of primary spinal cord tumor.
  • Pre-existing medical conditions such as uncontrolled tumor-related epilepsy, cardiopulmonary disease, or metabolic diseases that could exacerbate with exercise.
  • Patients with evidence of progressive CNS or systemic cancer in the last 3 months.
  • People who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
  • Actively on a weight loss diet.
  • Participate in more than 60 minutes of moderate or vigorous structured exercise/week.
  • Currently and regularly smokes.
  • Unable to travel to DFCI for necessary data collection.
  • May not be able to comply with the safety monitoring requirements of the study in the opinion of the investigator.

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Terapia di supporto
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: HIIT Exercise Program Group

Participants will be randomly assigned to the HIIT exercise group and receive:

  • 3x weekly for 16 week home-based virtually supervised High-Intensity Interval Training.
  • 16-week self-directed exercise follow up period.
  • 3 On-site visits at Week 1, 18 and 34 for assement testing and completion of questionnaires

Exercise program with stationary bike via the Zoom platform.

Altri nomi:
  • Allenamento ad intervalli ad alta intensità
Comparatore attivo: Control Group

Participants will be randomly assigned to the HIIT waitlist control group and receive:

  • Daily usual activities
  • 2 On-site visits at Week 1, and 18 for assement testing and completion of questionnaires
  • Option to complete 16 week, 3x weekly HIIT exercise program after initial 16 week period.

Usual Activities

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Attendance of Exercise Sessions
Lasso di tempo: From first exercise session to final exercise session, up to 16 weeks

Defined as participant attendance of >= 70% of the 48 HIIT exercise sessions.

From first exercise session to final exercise session, up to 16 weeks
Completion in Minutes of Exercise Sessions
Lasso di tempo: From first exercise session to final exercise session, up to 16 weeks

Defined as participant completion of >= 70% of the 90 minutes of exercise per week

From first exercise session to final exercise session, up to 16 weeks
HIIT Compliance
Lasso di tempo: From first exercise session to final exercise session, up to 16 weeks

Defined as obtaining +-5W of target power output for >= 40 seconds of high intensity minute

From first exercise session to final exercise session, up to 16 weeks
Barriers to Exercise Adherence
Lasso di tempo: From first exercise session to final exercise session, up to 16 weeks

Assessed through the 17-item Barriers to Recruitment Participation Questionnaire (BRPQ), 1-5 scale with 1 denoted as strongly agree and 5 as strongly disagree.

From first exercise session to final exercise session, up to 16 weeks
Participant Burden
Lasso di tempo: From first exercise session to final exercise session, up to 16 weeks

Assessed through the Perceived Research Burden Assessment (PRBA), 1-5 scale with 1 denoted as strongly disagree and 5 as strongly agree.

From first exercise session to final exercise session, up to 16 weeks

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Cognition
Lasso di tempo: : From baseline to post-intervention, up to 43 weeks

An assortment of tests will be executed through the NIH toolbox to measure overall cognition.

: From baseline to post-intervention, up to 43 weeks
Cardiorespiratory Fitness
Lasso di tempo: From baseline to post-intervention, up to 43 weeks

Assessed through the use of a VO2 max (or submaximal if equipment is unavailable) cycle exercise stress test (Parvo Medics TrueOne 2400; Sandy, UT, USA).

From baseline to post-intervention, up to 43 weeks
Muscular Strength
Lasso di tempo: From baseline to post-intervention, up to 43 weeks

10-repetition maximum will be used to assess muscular strength.

From baseline to post-intervention, up to 43 weeks
Body Composition
Lasso di tempo: From baseline to post-intervention, up to 43 weeks

Bioelectrical Impedance Analysis (BIA), and blood pressure as measured twice on both arms with a seated position with a minimum of 1-minute interval and the higher pressure will be recorded when there are differences.

BIA: Assessed via bioelectrical impedance using a validated device (Tanita 780, Arlington Heights, IL). Participants will be asked to remove their shoes and socks after which height will be taken using a stadiometer they will then proceed to move to the BIA and stand still on the device while holding the handles with their hands at their sides. The device will estimate body fat using an algorithm based on their age, sex, height, and body weight.

From baseline to post-intervention, up to 43 weeks
Fatigue
Lasso di tempo: From baseline to post-intervention, up to 43 weeks

BFI: A questionnaire of scale ratings 0 - 10 that focuses on cancer-related fatigue and tiredness.

From baseline to post-intervention, up to 43 weeks
Psychosocial Health
Lasso di tempo: From baseline to post-intervention, up to 43 weeks

Assessed through the Functional Assessment of Cancer Therapy-General (FACT-G) questionnaire, which is comprised of 27 items with scale ratings validated to measure physical, emotional, social, and functional well-being of cancer patients and survivors

From baseline to post-intervention, up to 43 weeks
Quality of Sleep
Lasso di tempo: From baseline to post-intervention, up to 43 weeks

Assessed through the Pittsburg Sleep Quality Index (PSQI), which is used to measure 7 components of the quality and patterns of sleep in participants.

From baseline to post-intervention, up to 43 weeks
Dietary Assessment, ASA-24
Lasso di tempo: Up to 3 days

Participants will be provided with a login to enter dietary data measured by an automated, online self-administered 24-hour assessment tool.

Up to 3 days
ActiGraph - Physical Activity Monitoring
Lasso di tempo: From baseline to post-intervention, up to 27 weeks

Participants will be provided with an accelerometer (ActiGraph, Pensacola, FL) to wear for seven days at baseline and post-intervention testing visits and will be instructed to wear the water-resistant accelerometer at all times except for when swimming or bathing. The device will record activity data and will be electronically transferred to a computer via USB cable at time of completion.

From baseline to post-intervention, up to 27 weeks
Exercise Tolerance
Lasso di tempo: From baseline to week 16, up to 32 weeks

Will be recorded using the Exercise-Induced Feeling Inventory (EIF). Based on a 0-4 scale, it assesses the participant's feeling state change(s) post-exercise and is also used for the assessment of self-motivation to adhere to an exercise regimen. Participants will be asked to complete the inventory before and after each exercise session.

From baseline to week 16, up to 32 weeks
Pain Index
Lasso di tempo: From baseline to post-intervention, up to 43 weeks

BPI: A 9 item questionnaire to evaluate the severity of pain and the impact of pain on the participant's daily functioning.

From baseline to post-intervention, up to 43 weeks
Hip and Waist Circumference
Lasso di tempo: From baseline to post-intervention, up to 43 weeks

Hip and waist circumference will be assessed and recorded in cm.

From baseline to post-intervention, up to 43 weeks

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Collaboratori

Investigatori

  • Investigatore principale: Christina Dieli-Conwright, PhD, MPH, Dana-Farber Cancer Institute

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

4 dicembre 2023

Completamento primario (Stimato)

24 settembre 2027

Completamento dello studio (Stimato)

24 settembre 2028

Date di iscrizione allo studio

Primo inviato

2 febbraio 2023

Primo inviato che soddisfa i criteri di controllo qualità

13 febbraio 2023

Primo Inserito (Effettivo)

23 febbraio 2023

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

6 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

3 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Altri numeri di identificazione dello studio

  • 22-505

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

The Dana-Farber / Harvard Cancer Center encourages and supports the responsible and ethical sharing of data from clinical trials. De-identified participant data from the final research dataset used in the published manuscript may only be shared under the terms of a Data Use Agreement. Requests may be directed to: [contact information for Sponsor Investigator or designee]. The protocol and statistical analysis plan will be made available on Clinicaltrials.gov only as required by federal regulation or as a condition of awards and agreements supporting the research.

Periodo di condivisione IPD

Data can be shared no earlier than 1 year following the date of publication

Criteri di accesso alla condivisione IPD

Contact the Belfer Office for Dana-Farber Innovations (BODFI) at innovation@dfci.harvard.edu

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .